BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

Dean Li will take over a Merck Research Laboratories that has been transformed by Roger Perlmutter over the past seven years, guiding a pharma that had been struggling with a patent cliff to the company...
BioCentury | Sep 19, 2020
Product Development

Sept. 18 ESMO roundup: data from Incyte, Autolus, Merck, Alkermes and Daiichi

Incyte moving into Phase III with PD-1 inhibitor retifanlimab for SCACIncyte Corp. (NASDAQ:INCY) reported its PD-1 inhibitor retifanlimab led to an objective response rate of 14% and a disease control rate of 49% in the...
BioCentury | Aug 11, 2020
Emerging Company Profile

GentiBio: combining trio of platforms to enhance Treg therapies

GentiBio launched this summer with a suite of technologies to develop next-generation Treg cell therapies that overcome several of the modality’s historical shortcomings, including stability and specificity....
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

Next-generation checkpoint inhibitors will take the limelight at the 2020 virtual ASCO meeting, with all eyes on TIGIT as the first to back up the noise with data. Genentech is poised to present Phase II...
BioCentury | May 15, 2020
Product Development

TIGIT emerges as a standout next generation checkpoint target at ASCO

Drugmakers have been searching for the next checkpoint inhibitor ever since CTLA-4 and PD-1 triggered the immuno-oncology movement roughly five years ago; however, most have disappointed in the clinic. New data presented at the 2020...
BioCentury | Oct 17, 2019
Preclinical News

Oct. 17 Preclinical Quick Takes: Miromatrix, Mayo extend vascular function in liver graft scaffold; plus James Allison-MD Anderson, Northwestern and Eleusis

...higher probabilities of hypophysitis or pneumonitis adverse events if patients had serum auto-antibodies against GNAL, ITM2B...
...GCase (GBA) - Glucosylceramidase beta; GNAL - G protein subunit α L; ITM2B (BRI2) - Integral membrane protein 2B BioCentury...
BioCentury | Dec 14, 2018
Financial News

Allen Insitute's immunology division launches with $125M, Lilly vet and five partners

The Allen Institute expects its latest research endeavor to generate knowledge about molecular drivers of immune-related diseases, paving the way for new diagnostics and therapies. The Allen Institute for Immunology launched on Dec. 12 with...
BioCentury | Dec 13, 2018
Preclinical News

Allen Institute's immunology division launches with $125M, Lilly vet and five partners

The Allen Institute expects its latest research endeavor to generate knowledge about molecular drivers of immune-related diseases, paving the way for new diagnostics and therapies. The Allen Institute for Immunology launched Wednesday with $125 million...
BioCentury | Aug 3, 2018
Clinical News

Amgen's Blincyto among negative CHMP opinions

EMA's CHMP released a handful of negative opinions July 27, including one for Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) and, on re-examination, negative recommendations for Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Eladynos abaloparatide-SC...
BioCentury | Jul 27, 2018
Company News

New Blincyto indication among negative CHMP opinions

EMA's CHMP released a handful of negative opinions Friday, including one for Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) and, on re-examination, negative recommendations for Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Eladynos abaloparatide-SC from...
Items per page:
1 - 10 of 74